Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.nejm.org › doi › fullEffect of Early Treatment with Ivermectin among Patients with...

   www.nejm.org › doi › full

   30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19),...

   • Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others

     We enrolled 654 patients in the BRAVE-AA1 trial and 546 in...

   • Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith

     A 53-year-old landscaper presented with a 4-month history of...

   • Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay

     Process guide for inferential studies using healthcare data...

   • Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes

     Nonspecific low back pain is diagnosed by ruling out other...

   • Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries

     Scalp hair regrowth is associated with improvements in...

   • Clinical Problem-Solving Looking Back L. Glick and Others

     On examination, the temperature was 36.1°C, the blood...

   • Correspondence Dec 15, 2022 Ivermectin Treatment for Covid-19

     Reis G, Silva EASM, Silva DCM, et al. Effect of early...

   • Editorial Audio Interview

     In this audio interview conducted on May 2, 2022, the...

2. pmc.ncbi.nlm.nih.gov › articles › PMC9308124Systematic review and meta-analysis of ivermectin for treatment...

   pmc.ncbi.nlm.nih.gov › articles › PMC9308124

   We conducted a comprehensive search on the impact of ivermectin for the management of patients with COVID-19 and observed that ivermectin does not have an effect in reducing mortality or mechanical ventilation in patients with COVID-19.

3. www.sciencedirect.com › science › articleEfficacy and safety of ivermectin for treatment of...

   www.sciencedirect.com › science › article

   1 sie 2024 · Five databases were searched until October 17, 2023, for randomized controlled trials (RCTs) in adult patients with COVID-19 treated with ivermectin against standard of care (SoC), placebo, or active drug. Primary outcomes were hospitalization, all-cause mortality, and adverse events (AEs).

4. www.nejm.org › doi › pdfToxic Effects from Ivermectin Use Associated with Prevention and...

   www.nejm.org › doi › pdf

   Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19. To the Editor: Ivermectin is approved by the Food and Drug Administration as an oral treat-ment for...

5. pmc.ncbi.nlm.nih.gov › articles › PMC8101859Effects of Ivermectin in Patients With COVID-19: A Multicenter,...

   pmc.ncbi.nlm.nih.gov › articles › PMC8101859

   A single dose of ivermectin was well-tolerated in symptomatic patients with COVID-19, and important clinical features of COVID-19 were improved with ivermectin use, including dyspnea, cough, and lymphopenia.

6. www.ncbi.nlm.nih.gov › pmc › articlesIvermectin as a multifaceted drug in COVID-19: Current insights

   www.ncbi.nlm.nih.gov › pmc › articles

   26 lip 2021 · For patients with COVID-19 who are, or may become, candidates for dexamethasone, it is reasonable to consider presumptive treatment with Ivermectin for moderate-to high-risk patients not previously tested or treated for Strongyloides.

7. pmc.ncbi.nlm.nih.gov › articles › PMC10071928Association between ivermectin treatment and mortality in...

   pmc.ncbi.nlm.nih.gov › articles › PMC10071928

   This study was designed with the primary objective of estimating the association of ivermectin treatment with mortality in patients admitted with COVID-19. A secondary objective was the estimation of the extent of reduction, if any, in duration of hospital stay in survivors who received ivermectin.